EUVIMEDEUVIMED entdecken
Crossref

Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base

Tyler Miluski, Bharosha Bhattarai, Taha Al-Shaikhly

Allergy and Asthma Proceedings · 2025

DOI: 10.2500/aap.2025.46.250078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy and Asthma Proceedings, 2025. Verfasst von Tyler Miluski und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Section of Allergy, Asthma, and Immunology, Penn State College of Medicine, Hershey, Pennsylvania and. Hauptthemen laut MEDLINE: Anaphylaxis, Adverse Drug Reaction Reporting Systems, Fluoroquinolones, Drug Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypersensitivity reactions, including anaphylaxis, have been increasingly reported with quinolones.

Objective

To characterize the association of different quinolones with anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS) data base.

Methods

We searched the FAERS data base for anaphylactic reaction reports (between 2015 and 2024) associated with the three commonly used fluoroquinolones in the United States, viz., levofloxacin, ciprofloxacin, and moxifloxacin. The reporting odds ratio (ROR) was used to assess disproportional reports of anaphylaxis among the individual fluoroquinolones and between the fluoroquinolones and all medications within the data base.

Results

We identified 941 anaphylaxis reports (ciprofloxacin, 390; levofloxacin, 299; and moxifloxacin, 252) of 89,351 adverse reactions reported for all fluoroquinolones between 2015 and 2024. There were disproportionally higher reports of anaphylaxis among fluoroquinolones compared with all medications within the data base (ROR 4.56 [95% confidence interval {CI}, 4.28-4.87]) but lower relative to that of amoxicillin (ROR 0.19 [95% CI, 0.17-0.20]). Within the fluoroquinolones, moxifloxacin was associated with the highest disproportionality signal for anaphylaxis relative to all other medications (ROR 8.65 [95% CI, 7.63-9.80]) and relative to all fluoroquinolones (ROR 1.90 [95% CI, 1.65-2.18]), whereas levofloxacin was associated with a disproportionally lower signal when compared with all other fluoroquinolones (ROR 0.77 [95% CI, 0.67-0.88]). The disproportionally higher anaphylaxis report associated with moxifloxacin was especially pronounced among women (ROR 2.11 [95% CI, 1.78-2.49]) and elderly individuals (ROR 2.74 [95% CI, 2.15-3.48]).

Conclusion

Moxifloxacin is associated with relatively higher anaphylaxis reports when compared with all other quinolones, especially among female and elderly individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisAdverse Drug Reaction Reporting SystemsFluoroquinolonesDrug HypersensitivityAnti-Bacterial AgentsHumansUnited StatesUnited States Food and Drug AdministrationFemaleMaleAdultMiddle AgedDatabases, FactualAgedAdolescentYoung AdultChildLevofloxacinChild, PreschoolInfant

Substanzen

FluoroquinolonesAnti-Bacterial AgentsLevofloxacin

Autor:innen und Institutionen

  • From the Section of Allergy, Asthma, and Immunology, Penn State College of Medicine, Hershey, Pennsylvania and.
  • Department of Medicine, Penn State College of Medicine, 500 University Drive, PO Box 850, Hershey, Pennsylvania.

Zitieren

APA

Miluski, T., Bhattarai, B., & Al-Shaikhly, T. (2025). Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2025.46.250078

Vancouver

Miluski T, Bhattarai B, Al-Shaikhly T. Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base. Allergy and Asthma Proceedings. 2025. doi:10.2500/aap.2025.46.250078

BibTeX
@article{Miluski2025,
  author = {Miluski, Tyler and Bhattarai, Bharosha and Al-Shaikhly, Taha},
  title = {Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base},
  journal = {Allergy and Asthma Proceedings},
  year = {2025},
  doi = {10.2500/aap.2025.46.250078}
}
Kostenlos starten →